Aurinia launches mid-stage study of voclosporin in dry eye syndrome; shares up 2% after hours

|By:, SA News Editor

Aurinia Pharmaceuticals (NASDAQ:AUPH) initiates a Phase 2 clinical trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). It will compare VOS 0.2% against Allergan's (NYSE:AGN) RESTASIS (cyclosporine ophthalmic emulsion 0.05%) over a four-week treatment period in 90 patients with mild-to-moderate DES.

The primary endpoint will be tolerability. Secondary endpoints include efficacy measures. The trial should be completed by year-end.

Shares are up 2% after hours.

Subscribe for full text news in your inbox